| Literature DB >> 23935756 |
Aihua Shu1, Leyun Zhan, Haibin Fang, En Lv, Xiaobo Chen, Mingyu Zhang, Qiang Wang.
Abstract
Heart rate variability (HRV) was used in the present study to evaluate a target-controlled approach compared with a constant-rate infusion for remifentanil anesthesia during off-pump coronary artery bypass grafting (OP-CABG) surgery. A total of 65 patients with American Society of Anesthesiologists (ASA) physical status II or III, who were aged 60-85 years and scheduled for OP-CABG, were selected for the study. All patients were administered an intramuscular premedication of 10 mg morphine and 0.3 mg scopolamine. In group I, remifentanil was infused using a target-controlled approach at 1.5-5.0 ng/ml, and in group II, remifentanil was infused at a constant-rate of 0.05-1.0 μg/kg/min and at additional single increments of 1 μg/kg when appropriate. The heart rate and other hemodynamic monitoring indices of the patients, including the mean arterial pressure, central venous pressure, pulmonary artery pressure and pulmonary capillary wedge pressure, were monitored at various time points, including prior to induction (T0), at extubation (performed intraoperatively; T7) and at 24 h post-surgery. The HRV indices, including total power (TP), low frequency (LF) and the LF/high frequency (HF) ratio of power (LF/HF), were reduced following induction at T0 and remained low at 24 h post-surgery. At T5 (right coronary or left circumflex artery anastomosis) and T7 (tracheal extubation), all the HRV indices, with the exception of the HF power, were significantly increased (P<0.05). Additionally, the TP, LF and LF/HF values in group II were higher at T5 compared with those in group I (P<0.05). Remifentanil target-controlled infusion is superior to constant-rate infusion in suppressing the stress response during OP-CABG, maintaining the balance of the cardiac autonomic nervous system and promoting the recovery of the autonomic function following surgery.Entities:
Keywords: heart rate variability; off-pump coronary artery bypass grafting; remifentanil; target-controlled infusion
Year: 2013 PMID: 23935756 PMCID: PMC3735586 DOI: 10.3892/etm.2013.1108
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of general characteristics between the groups.
| Characteristics | Group I (n=32) | Group II (n=33) |
|---|---|---|
| Gender (male/female) | 25/7 | 24/9 |
| Age (years) | 68.5±10.7 | 67.9±10.5 |
| Body weight (kg) | 68.2±11.1 | 67.1±10.7 |
| LVEF value (%) | 53.9±7.0 | 54.3±6.9 |
| Remifentanil dosage (mg) | 1.68±0.29 | 1.65±0.28 |
| Metoprolol dosage (mg/day) | 55.8±21.2 | 55.4±20.8 |
| Duration of surgery (min) | 239.0±33.2 | 239.5±33.7 |
| Number of bypasses | 3.8±1.1 | 3.8±1.2 |
| Nitroglycerin dosage (mg) | 12.9±2.4 | 13.3±2.2 |
| Dopamine dosage (mg) | 36.4±8.1 | 35.9±8.8 |
| Norepinephrine dosage ( | 188.3±20.7 | 191.4±19.5 |
| Esmolol dosage (mg) | 22.4±7.1 | 23.1±7.6 |
| Phenylephrine dosage ( | 56.4±8.2 | 103.8±13.7 |
P<0.05 compared with group I (t-test). All data are presented as the mean ± SD with the exception of gender. LVEF, left venticular ejection fraction; SD, standard deviation.
Changes in hemodynamic indices in group I (n=32) and group II (n=33) during the perioperative period at various time points.
| Indices | T0 | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 |
|---|---|---|---|---|---|---|---|---|---|
| HR (bpm) | |||||||||
| I | 56.9±7.4 | 55.6±6.5 | 56.8±6.8 | 58.1±7.0 | 56.4±6.5 | 56.0±6.6 | 56.2±7.0 | 69.8±9.5 | 58.2±6.8 |
| II | 56.8±7.5 | 55.6±6.8 | 56.9±7.0 | 57.9±6.8 | 56.7±6.9 | 56.2±7.0 | 56.4±7.1 | 69.8±9.7 | 58.7±7.3 |
| MAP (mmHg) | |||||||||
| I | 72.3±11.6 | 69.9±10.2 | 71.1±11.2 | 72.2±10.4 | 71.5±9.9 | 69.3±10.7 | 72.1±10.2 | 82.1±10.8 | 74.1±10.5 |
| II | 72.6±12.0 | 69.7±10.1 | 71.3±10.7 | 72.5±10.3 | 72.0±9.7 | 69.7±10.1 | 71.6±10.5 | 86.2±10.9 | 74.1±10.5 |
| CVP (mmHg) | |||||||||
| I | 4.7±0.8 | 4.8±0.9 | 4.8±0.6 | 4.8±0.5 | 5.0±0.8 | 5.1±0.9 | 5.1±0.6 | 5.1±0.7 | 5.0±0.9 |
| II | 4.7±1.0 | 4.8±0.8 | 4.9±0.9 | 4.8±0.6 | 5.0±0.6 | 5.2±0.8 | 5.0±0.8 | 5.2±1.1 | 5.1±0.9 |
| PAP (mmHg) | |||||||||
| I | 18.6±5.1 | 19.1±4.9 | 18.9±4.4 | 18.9±4.8 | 19.3±4.9 | 19.5±5.1 | 18.9±5.1 | 19.1±5.0 | 18.8±5.0 |
| II | 18.7±4.9 | 19.1±5.0 | 18.8±4.8 | 19.0±4.7 | 19.4±4.9 | 19.4±5.1 | 19.2±5.0 | 19.3±5.2 | 18.7±5.1 |
| PCWP (mmHg) | |||||||||
| I | 10.8±2.2 | 10.7±2.1 | 10.9±2.2 | 11.0±1.8 | 10.7±1.9 | 11.1±2.1 | 11.0±1.8 | 10.7±1.9 | 10.8±2.1 |
| II | 10.7±2.1 | 10.7±2.2 | 10.9±2.3 | 11.0±1.9 | 10.8±2.1 | 10.9±2.1 | 11.0±1.8 | 10.8±1.9 | 10.9±2.2 |
P<0.05 compared with T0 (t-test). All data are presented as the mean ± SD. HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; SD, standard deviation.
Changes in the plasma levels of E, COR, BG and LAC in group I (n=32) and group II (n=33) at various time points.
| Indices | T0 | T2 | T3 | T5 | T6 | T7 | T8 |
|---|---|---|---|---|---|---|---|
| E (pg/ml) | |||||||
| I | 105±25 | 108±29 | 107±22 | 102±22 | 108±29 | 318±86 | 108±25 |
| II | 106±23 | 110±27 | 104±30 | 101±24 | 104±20 | 327±74 | 109±27 |
| COR (ng/ml) | |||||||
| I | 76.6±15.8 | 74.2±14.9 | 79.8±10.6 | 75.8±16.5 | 75.8±15.8 | 98.1±20.9 | 80.1±16.6 |
| II | 78.3±16.1 | 74.8±15.1 | 79.9±10.9 | 76.5±15.9 | 76.0±14.9 | 99.2±21.8 | 80.3±17.8 |
| BG (mmol/l) | |||||||
| I | 5.3±0.8 | 5.1±0.9 | 7.1±1.1 | 7.3±1.4 | 7.4±1.9 | 7.5±1.1 | 5.6±0.9 |
| II | 5.5±0.9 | 5.6±0.7 | 7.4±1.2 | 9.4±2.5[ | 10.4±1.8[ | 10.9±2.1[ | 5.9±1.0 |
| LAC (mmol/l) | |||||||
| I | 0.9±0.3 | 1.0±0.3 | 1.7±0.5 | 1.8±0.4 | 1.7±0.2 | 1.6±0.3 | 1.0±0.4 |
| II | 1.0±0.3 | 1.0±0.4 | 1.8±0.6 | 2.9±0.3[ | 2.4±0.2[ | 2.2±0.3[ | 1.0±0.4 |
P<0.05 compared with T0;
P<0.05 compared with Group I. All data are presented as the mean ± SD. E, epinephrine; COR, cortisol; BG, blood glucose; LAC, lactate; SD, standard deviation.
Changes in HRV in group I (n=32) and group II (n=33) at various time points.
| Indices | T0 | T2 | T3 | T5 | T6 | T7 | T8 |
|---|---|---|---|---|---|---|---|
| TP (msec2/Hz) | |||||||
| I | 3.25±0.41 | 2.48±0.29 | 2.45±0.61 | 4.55±0.52 | 2.65±0.31 | 5.75±0.82 | 2.35±0.32 |
| II | 3.29±0.39 | 2.43±0.31 | 2.55±0.67 | 5.85±0.71[ | 2.85±0.34 | 5.80±0.90 | 2.39±0.37 |
| LF (msec2/Hz) | |||||||
| I | 2.65±0.33 | 1.94±0.35 | 1.86±0.41 | 3.96±0.73 | 2.03±0.38 | 5.09±0.93 | 1.72±0.63 |
| II | 2.67±0.34 | 1.96±0.33 | 1.87±0.39 | 5.09±0.79[ | 2.06±0.39 | 5.13±0.89 | 1.75±0.60 |
| HF (msec2/Hz) | |||||||
| I | 2.29±0.25 | 1.57±0.29 | 1.54±0.25 | 1.50±0.35 | 1.51±0.37 | 1.72±0.31 | 1.64±0.24 |
| II | 2.31±0.29 | 1.59±0.26 | 1.53±0.23 | 1.51±0.32 | 1.50±0.33 | 1.68±0.35 | 1.62±0.27 |
| LF/HF | |||||||
| I | 1.79±0.86 | 1.26±0.52 | 1.22±0.36 | 2.75±0.96 | 1.28±0.56 | 3.36±0.86 | 1.39±0.56 |
| II | 1.78±0.84 | 1.28±0.56 | 1.23±0.40 | 3.86±1.16[ | 1.29±0.56 | 3.40±0.91 | 1.43±0.61 |
P<0.05 compared with T0;
P<0.05 compared with Group I. All data are presented as the mean ± SD. HRV, heart rate variability; SD; standard deviation; TP, total power; LF, low frequency power; HF, high frequency power; LF/HF, LF/HF power ratio.
Figure 1.Changes in HRV in group I and group II. Data are presented as the mean ± SD, group I (n=32), group II (n=33). TP, total power; LF, low frequency; HF, high frequency; LF/HF, LF/HF power ratio; HRV, heart rate variability; SD, standard deviation.